2-(2-chlorobenzylidene)hydrazinecarboximidamide | 13098-73-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(2-chlorobenzylidene)hydrazinecarboximidamide
• 英文别名: sephin1；Sephin 1；2-[(2-chlorophenyl)methylideneamino]guanidine
• CAS: 13098-73-2
• 化学式: C₈H₉ClN₄
• mdl: MFCD00790608
• 分子量: 196.639
• InChiKey: PDWJALXSRRSUHR-UHFFFAOYSA-N

物化性质

• 溶解度：
  不溶于水；不溶于乙醇； ≥7.75 mg/mL，溶于 DMSO

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  76.8
• 氢给体数：
  2
• 氢受体数：
  2

制备方法与用途

(E/Z)-冰rguastat是一种选择性抑制剂，能够作用于磷酸酶调节亚单元PPP1R15A（R15A）。此外，(E/Z)-冰rguastat还可用于研究蛋白质错误折叠相关疾病。

反应信息

• 作为反应物：
  描述：

  2-(2-chlorobenzylidene)hydrazinecarboximidamide 以 甲醇 、 乙腈 为溶剂， 生成 methyl 2-(2-((N''-(2-chlorobenzylidene)carbamohydrazonoyl)imino)-3-(3-methoxyphenyl)-4-oxothiazolidin-5-ylidene)acetate
  参考文献：
  名称：

  Antiproliferative activity and molecular docking studies of new 4-oxothiazolidin-5-ylidene acetate derivatives containing guanylhydrazone moiety

  摘要：

  DOI：

  10.1016/j.molstruc.2022.132627
• 作为产物：
  描述：

  2-氯苯甲醛 、 氨基胍硝酸盐 在 水 、 sodium hydroxide 作用下， 生成 2-(2-chlorobenzylidene)hydrazinecarboximidamide
  参考文献：
  名称：

  新型嘧啶-色基杂化衍生物作为潜在抗增殖剂的有效合成和分子对接研究

  摘要：

  摘要 含有嘧啶核 5 H-色基[4,3- d ]嘧啶（4a-c，e-h，l-r，t）和嘧啶-5-基-（2-羟基苯基）甲酮（5a，c , d , f–k , m–o , r , s , u)由脒腙(2a–u)和 3-甲酰基色酮(3)反应合成. 使用 MTT 分析方法针对人肝肝细胞癌细胞系 (HepG2) 和人乳腺腺癌细胞系 (MDA-MB-231) 测试了这些化合物。此外，还进行了分子对接计算，以比较各种新型杂环化合物对癌症蛋白质的生物活性。在这些计算中，使用的蛋白质是来自乳腺癌相关蛋白 1JNX 的 BRCT 重复区域的晶体结构、VEGFR 激酶（肝癌）蛋白的晶体结构、3WZE，以及变构 Eya2 磷酸盐抑制剂（肺癌）的晶体结构蛋白质，5ZMA，分别。经过分子对接计算、吸收、分布、代谢，

  DOI：

  10.1080/00397911.2021.1922920

文献信息

• Synthesis, Antileishmanial Activity and in silico Studies of Aminoguanidine Hydrazones (AGH) and Thiosemicarbazones (TSC) Against Leishmania chagasi Amastigotes
  作者：Thiago M. de Aquino、Paulo H. B. França、Érica E. E. S. Rodrigues、Igor. J.S. Nascimento、Paulo F. S. Santos-Júnior、Pedro G. V. Aquino、Mariana S. Santos、Aline C. Queiroz、Morgana V. Araújo、Magna S. Alexandre-Moreira、Raiza R. L. Rodrigues、Klinger A. F. Rodrigues、Johnnatan D. Freitas、Jacques Bricard、Mario R. Meneghetti、Jean-Jacques Bourguignon、Martine Schmitt、Edeildo F. da Silva-Júnior、João X. de Araújo-Júnior

  DOI：10.2174/1573406417666210216154428

  日期：2022.2

  Leishmaniasis is a worldwide health problem, highly endemic in developing countries. Among the four main clinical forms of the disease, visceral leishmaniasis is the most severe, fatal in 95% of cases. The undesired side-effects from first-line chemotherapy and the reported drug resistance search for effective drugs that can replace or supplement those currently used an urgent need. Aminoguanidine hydrazones (AGH's) have been explored for exhibiting a diverse spectrum of biological activities, in particular the antileishmanial activity of MGBG. The bioisosteres thiosemicarbazones (TSC's) offer a similar biological activity diversity, including antiprotozoal effects against Leishmania species and Trypanosoma cruzi.

  Considering the impact of leishmaniasis worldwide, this work aimed to design, synthesize, and perform a screening upon L. chagasi amastigotes and for the cytotoxicity of the small "in-house" library of both AGH and TSC derivatives and their structurally-related compounds.

  A set of AGH's (3-7), TSC's (9, 10), and semicarbazones (11) were initially synthesized. Subsequently, different semi-constrained analogs were designed and also prepared, including thiazolidines (12), dihydrothiazines (13), imidazolines (15), pyrimidines (16, 18) azines (19, 20), and benzotriazepinones (23-25). All intermediates and target compounds were obtained with satisfactory yields and exhibited spectral data consistent with their structures. All final compounds were evaluated against L. chagasi amastigotes and J774.A1 cell line. Molecular docking was performed towards trypanothione reductase using GOLD® software.

  The AGH's 3i, 4a, and 5d, and the TSC's 9i, 9k, and 9o were selected as valuable hits. These compounds presented antileishmanial activity compared with pentamidine, showing IC50 values ranged from 0.6 to 7.27 μM, maximal effects up to 55.3%, and satisfactory SI values (ranged from 11 to 87). On the other hand, most of the resulting semi-constrained analogs were found cytotoxic or presented reduced antileishmanial activity. In general, TSC class is more promising than its isosteric AGH analogs, and the beneficial aromatic substituent effects are not similar in both series. In silico studies have suggested that these hits are capable of inhibiting the trypanothione reductase from the amastigote forms.

  The promising antileishmanial activity of three AGH’s and three TSC’s was characterized. These compounds presented antileishmanial activity compared with PTD, showing IC50 values ranged from 0.6 to 7.27 μM, and satisfactory SI values. Further pharmacological assays involving other Leishmania strains are under progress, which will help to choose the best hits for in vivo experiments.

  背景：利什曼病是全球性健康问题，在发展中国家高度流行。在该病的四种主要临床形式中，内脏利什曼病是最严重的，95%的病例会致命。由于一线化疗药物的不良副作用和报道的药物耐药性，迫切需要寻找可以替代或补充当前使用的有效药物。氨基胍脒肼酮（AGH）已被探索用于展示多样的生物活性，特别是MGBG的抗利什曼病活性。生物同功异构体硫脲半胱氨酮（TSC）提供类似的生物活性多样性，包括对利什曼病和克氏锥虫的抗原虫效应。 目的：考虑到利什曼病在全球范围内的影响，本研究旨在设计、合成并对L. chagasi阿马斯蒂果虫进行筛选，以及对小型“内部”AGH和TSC衍生物及其结构相关化合物的细胞毒性进行评估。 方法：首先合成了一组AGH（3-7）、TSC（9, 10）和半胱氨酮（11）。随后，设计并制备了不同的半约束类似物，包括噻唑烷（12）、二氢噻嗪（13）、咪唑烷（15）、嘧啶（16, 18）、吲哚烷（19, 20）和苯并三唑环酮（23-25）。所有中间体和目标化合物均以满意的收率获得，并展示了与其结构一致的光谱数据。所有最终化合物均对L. chagasi阿马斯蒂果虫和J774.A1细胞系进行了评估。使用GOLD®软件对其进行了针对巯基还原酶的分子对接。 结果：AGH的3i、4a和5d以及TSC的9i、9k和9o被选为有价值的命中物。这些化合物与五环胺相比具有抗利什曼病活性，IC50值范围从0.6到7.27μM，最大效果高达55.3％，满意的SI值（范围从11到87）。另一方面，大多数结果的半约束类似物被发现具有细胞毒性或具有降低的抗利什曼病活性。总体而言，TSC类比其同功异构AGH类更有前景，而有益的芳香族取代作用在两个系列中并不相似。计算机模拟研究表明这些命中物能够抑制阿马斯蒂果虫的巯基还原酶。 结论：三种AGH和三种TSC的有前景的抗利什曼病活性得到了表征。这些化合物与PTD相比具有抗利什曼病活性，IC50值范围从0.6到7.27μM，SI值满意。正在进行涉及其他利什曼病菌株的进一步药理学评估，这将有助于选择最佳的命中物进行体内实验。
• [EN] METHOD OF TREATING CANCER WITH A COMBINATION OF BENZYLIDENEGUANIDINE DERIVATIVES AND CHEMOTHERAPEUTIC AGENT.<br/>[FR] PROCÉDÉ DE TRAITEMENT DE CANCER AVEC UNE COMBINAISON DE DÉRIVÉS DE BENZYLIDÈNEGUANIDINE ET D'AGENT CHIMIOTHÉRAPEUTIQUE
  申请人：INFLECTIS BIOSCIENCE

  公开号：WO2017021216A1

  公开（公告）日：2017-02-09

  The present invention relates to a composition for use in treating a glioma or ameliorating the effects of a glioma, particularly glioblastoma, wherein said composition comprises a first active agent selected from the group consisting of a compound of formula (I), or a pharmaceutically acceptable salt thereof, (I) and a second active agent, which is temozolomide, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

  本发明涉及一种用于治疗胶质瘤或改善胶质瘤效果，特别是胶质母细胞瘤的组合物，所述组合物包括选自以下化合物组的第一活性剂，即化合物(I)或其药学上可接受的盐(I)，以及第二活性剂，即替莫唑胺或其药学上可接受的盐；以及一种药学上可接受的载体。
• [EN] NOVEL THERAPEUTIC USES OF BENZYLIDENEGUANIDINE DERIVATIVES FOR THE TREATMENT OF PROTEOPATHIES<br/>[FR] NOUVELLES UTILISATIONS THÉRAPEUTIQUES DE DÉRIVÉS DE LA BENZYLIDÈNE-GUANIDINE DANS LE TRAITEMENT DE PROTÉOPATHIES
  申请人：INFLECTIS BIOSCIENCE

  公开号：WO2016001389A1

  公开（公告）日：2016-01-07

  The present invention relates to novel uses of a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof, in treating a disorder associated with the PPP1R15A pathway and associated with protein misfolding stress and in particular with accumulation of misfolded proteins selected in the group of tauopathies, synucleinopathies, polyglutamine and polyalanine diseases, leukodystrophies, cystic fibrosis, multiple sclerosis, lysosomal storage disorders, amyloidosis diseases, inflammation, metabolic disorders, cardio-vascular disorders, osteoporosis, nervous system trauma, ischemia.

  本发明涉及一种化合物（I）的新用途，或其互变异构体和/或药用盐，在治疗与PPP1R15A途径相关的紊乱，与蛋白质错误折叠应激相关，特别是与在tau病、α-突触核蛋白病、多聚谷氨酸和多聚丙氨酸疾病、白质病、囊性纤维化、多发性硬化、溶酶体贮积疾病、淀粉样变性疾病、炎症、代谢紊乱、心血管疾病、骨质疏松症、神经系统创伤、缺血等相关的错误折叠蛋白的积累。
• Synthesis of novel heterocyclic compounds containing pyrimidine nucleus using the Biginelli reaction: Antiproliferative activity and docking studies
  作者：Sevtap Çağlar Yavuz、Senem Akkoç、Burçin Türkmenoğlu、Emin Sarıpınar

  DOI：10.1002/jhet.3978

  日期：2020.6

  guanyl hydrazone derivatives (3a‐n) . These compounds were tested as in vitro against two types of cancerous cell lines, namely, a human colon cancerous cell line (DLD‐1) and a human breast cancerous cell line (MDA‐MB‐231). According to the obtained results, nearly all the compounds have cytotoxic activity in the tested cell lines. Especially, the compounds 4j , 4k , and 4n had a significant effect against

  在一个反应​​步骤中，由芳香醛（1），氰基乙酸乙酯（2）和一些some衍生物（3a-n​​）的三重反应合成了嘧啶衍生物（4a-p ）。这些化合物在体外针对两种类型的癌细胞系进行了测试，分别是人结肠癌细胞系（DLD-1）和人乳腺癌细胞系（MDA-MB-231）。根据获得的结果，几乎所有化合物在测试的细胞系中均具有细胞毒活性。尤其是化合物4j，4k和4n对DLD-1具有明显的影响。此外，化合物4g，4m，和4o相比，针对MDA-MB-231的其他合成化合物，IC 50值更低。我们希望这些化合物将来可以作为抗癌药得到改进。根据拓扑异构酶I和N-乙酰转移酶1蛋白进行分子对接，从理论上检查具有最佳活性的嘧啶化合物的结合模式和位点。
• Synthesis and Biological Activities of 2-Amino-1-arylidenamino Imidazoles as Orally Active Anticancer Agents
  作者：Wen-Tai Li、Der-Ren Hwang、Jen-Shin Song、Ching-Ping Chen、Jiunn-Jye Chuu、Chih-Bo Hu、Heng-Liang Lin、Chen-Lung Huang、Chiung-Yi Huang、Huan-Yi Tseng、Chu-Chung Lin、Tung-Wei Chen、Chi-Hung Lin、Hsin-Sheng Wang、Chien-Chang Shen、Chung-Ming Chang、Yu-Sheng Chao、Chiung-Tong Chen

  DOI：10.1021/jm901501s

  日期：2010.3.25

  2-Amino-1-arylidenaminoimidazoles, a novel class of orally (po) active microtubule-destabilizing anticancer agents, were synthesized. The compounds were designed from a hit compound identified in a drug discovery platform by using cancer cell-based high throughput screening, assay. Selective synthesized compounds exerted cell cytotoxicity against human cancer cells. The underlying mechanisms for the anticancer activity were demonstrated as interacting with the tubulins and inhibiting, microtubule assembly, leading to proliferation inhibition and apoptosis induction in the human tumor cells. Furthermore, two compounds showed in vivo anticancer activities in both po and intravenously (iv) administered routes and prolonged the life spans of murine leukemic P388 cells-inoculated mice. These new po active anti mitotic anticancer agents are to be further examined in preclinical studies and developed for clinical uses.